Enzyme inhibitors of PAI-1
AssigneesAmano Enzyme U.S.A. Co., Ltd., Amano Enzyme Inc.
InventorJames F. Jolly
Life of this patent
Estimating the term…
Abstract
The invention provides a method for the treatment of a subject suffering from a cardiovascular disease using a therapeutically effective amount of at least one enzyme that is capable of inhibiting PAI-1 activity. The invention also provides a method of decreasing the risk of the occurrence of a cardiovascular disease in a subject who presents at least one risk factor that is associated with a cardiovascular disease, by administering to the subject a therapeutically effective amount of at least one enzyme that is capable of inhibiting PAI-1 activity. Additionally, the invention provides a method of inhibiting PAI-1 activity in a subject in need thereof, where the subject is administered an enzyme selected from a protease or peptidase.
Claims8
A method of inhibiting plasminogen activator inhibitor type 1 (PAI-1)activity in a subject in need thereof having a greater than normal blood level of PAI-1 activity, comprising orally administering to the subject an effective amount of at least one enzyme selected from the group consisting of semi-alkaline protease, bromelain, serapeptase, pronase, and papain.
Dependencies are inferred from the claim text.